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ABSTRACT 
Establishing a relationship of causality between the medications received and the events occurred utilizing causality assessment scale is much needed to 
reduce the occurrence of Adverse Drug Reactions (ADRs) and to prevent exposure of patients towards additional drug hazards. Causality assessment 
can be defined as the determination of chance, whether a selected intervention is the root cause of the adverse event observed. The causality assessment 
is the responsibility of either a single expert or an established committee. As it is a common phenomenon of variable perception of knowledge and 
experience by each expert, there is a high possibility of disagreement and inter-individual variability on assessment. Many of the causality assessment 
methods have their advantages and disadvantages. However, no single scale has been adopted as standardized and considered for uniform acceptance. 
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INTRODUCTION 
Pharmacovigilance is an integral branch of the science which is related 
to collection, detection, assessment, understanding, and prevention of 
adverse effects or any other problems related to drug use [1]. World 
Health Organization (WHO) defined the ADR as “response to a drug, 
which is noxious and unintended, and which occurs at doses normally 
used in man for prophylaxis, diagnosis or therapy of disease, or for the 
modification of physiological function [2]. This definition excludes 
overdose, abuse of the drug, treatment failure and drug administration 
errors. The female gender, age (very young and very old), multiple 
medications and the physiological state of renal and liver function, 
breastfeeding, pregnancy, and alcohol intake are considered as the 
important risk factors for ADRs [3]. 
Adverse drug effects not only entirely intrude with the patient’s 
compliance towards the treatment, but they also additionally 
increase morbidity and mortality, which also reflects on the financial 
burden of the society. Of the total ADRs estimated 6.7% (range 1.2-
24.1%) was identified in hospitalized patients and of that 0.32% 
(0.1-0.85%) being fatal [4]. In a South Indian study, about 3.7% of 
the total hospitalized patients were observed to be suffering from 
ADRs, and among them, 1.3% were fatal. About 0.7% of the 
hospitalizations were because of ADRs [5]. A study conducted by 
Arulmani et al. reported that among the collected ADR reports in the 
hospital, 3.4% of ADR related cases were approved to require 
hospitalization and 3.7% ADRs developed in the patients during the 
period of hospitalization [6]. In recent times, the meta-analysis by 
Alhawassi et al. [7]. Which included 14 studies found 10.0% (95%CI, 
7.2–12.8%) hospitalizations because of ADRs, amidst inpatients over 
65 y of age; this study determined that hospitalization of one in ten 
is because of ADRs. Data indicates that 19.18% higher death rate and 
8.25% increased length of hospital stay among inpatients that 
experience ADRs. It has been estimated that patients with ADRs 
suffer an average increase of 19.86% in their total medical costs [8].  
In a systematic review conducted on 25 observational studies, the 
percentage of hospitalizations due to ADRs was 4% among children, 
6% among adults, and 11% among older adults [9-10]. The potential 
to suspect or identify adverse events with plausible explanations and 
standard measures to avoid inappropriate management of ADRs is 
expected from clinicians and clinical pharmacists. Establishing or 
evaluating likelihood between the adverse event and the drug through 
causality assessment is much needed to reduce the occurrence of 
ADRs and to prevent exposure of patients towards additional drug 
hazards [11]. It is a key element of Pharmacovigilance and 
contributes to evaluate risk-benefit profiles and identify signals, 
thereby assisting in regulatory decision making [13]. 
Informal causality assessment of ADRs is in general practice by 
healthcare professionals to conclude decisions regarding therapy 
management [12]. Algorithms should provide more objective 
decision on causality rather than theoretical explanation in 
identifying adverse events during therapy. The four basic principles 
underlying the objective causal assessment include-1) temporal 
eligibility, 2) dechallenge and outcome, 3) rechallenge and outcome, 
and 4) confounding factors [14]. The current review article focuses 
on the merits and demerits of different assessment scales and briefs 
the use of a specific scale for a given clinical practice setup. 
Methods of causality assessment 
To characterize ADRs, research workers identified several causality 
assessment methods based on different criteria such as analogous 
scales, theorems, probability scales, algorithms, etc. however, inter-
rater and intra-rater variability are wide as there is no predefined 
diagnostic criteria or classifications [15, 16]. 
Until now, not a single causality assessment scale has been accepted 
and adopted universally due to variability and inconsistency in 
reproducibility and validity [17]. 
A High incidence of ADRs arises during the treatment at tertiary care 
hospitals [22]. Hence causality assessment at such instances 
contributes to i) early identification of ADRs and minimization of 
further complications ii) Optimized therapy [23]; iii) new strategical 
treatment to avoid recurrence iv) Cost minimization by reducing 
prolonged hospitalization [24]. 
Source of information and search strategy for identifying 
relevant studies 
To ensure a comprehensive research review of the subject, we 
performed searches using terms such as medical subject headings 
(MeSH) and key text words, such as “causality assessment scales,” 
“causality evaluation”, “methods for causality assessment”, “tools for 
causality assessment”, “algorithm for causality” published till 2018. 
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Thus, the abstracts of published studies with relevant information 
on the drug information centers were identified. These terms were 
used individually and in combination to ensure an extensive 
literature search. Relevant articles were selected and collated based 
on the broader objective of the review. This was achieved by 
searching databases, including SCOPUS, Web of Science, and Embase. 
From this common methodology, discoveries and findings were 
identified and summarized in this final review. 
Detailed classification 
The probability of relative impact between the adverse event and 
the drug is usually estimated by the physicians or clinical 
pharmacologists/pharmacists in a hospital setting, as they are 
responsible for recognizing or suspecting most of the ADRs during 
treatment [12]. The causality assessment is the responsibility of 
either a single expert or an established committee. As it is a common 
phenomenon of variable perception of knowledge and experience by 
each expert, there is a high possibility of disagreement and inter-
individual variability on assessment. Various methods of causality 
assessment are described here. 
Swedish method by Wilholm et al. 1984 
Swedish method was confined to the regulatory agency of Sweden. 
Seven factors are considered by the clinician to assess the causal 
relationship: (i) the time sequence, (ii) previous medication history, 
(iii) dose correlation, (iv) The pattern of response to drugs, (v) drug 
rechallenge, (vi) alternative causes for etiology and (vii) concurrent 
medications received. Events due to drugs are allocated as probable 
or possible and non-assessable or unlikely. 
Limitation: Huge chance of overlap and evaluation errors of ADRs 
can be occurred due to low categorical choices of assessment of 
causality is the considerable limitation for this method [25] 
Dangaumou’s french method 
French regulatory agency used this method since 1977. The method 
uses two different tables containing three chronological and four 
semiological criteria’s. The chronological/sequential principles are 
(i) challenge of drugs, (ii) dechallenge and (iii) rechallenge, with a 
comprehensive score of four possible categories. The semiological 
principles include (i) Clinical signs present (ii) favoring elements, 
(iii) Alternative explanation not related to drugs (none or possible) 
and (iv) Three possible results (positive, negative or no test for the 
event-drug pair) to specific lab test. Assessment is classified into 
likely, possible and dubious. 
The stated method has the benefit of separate analysis of each drug 
and it grants certain drugs at a time excluding the suspected drug. 
Limitation: The only limitation of the stated method is it consumes 
more time and analysis compared to alternative algorithms [26]. 
Kramer et al. 1974 method 
This method is applicable for the assessment of single suspect drugs 
and in the case of multiple drug administration, each one is 
separately assessed. Kramer’s method is known for its transparency. 
Limitation: Effective utilization of this method requires certain 
levels of experience, time and expertise [27]. 
Balanced assessment method (Lagier et al. 1983) 
Evaluation can be done for case reports considering the likelihood of 
each criterion. Consideration of the possibility for alternative causes 
of each factor is the main advantage of this scale. Two independent 
assessors need to evaluate this scale; however, the evaluation still 
varies based on their level of expertise and knowledge. 
Limitation: Assessors should be expertise in the relevant field to 
make efficient and determined evaluation [28]. 
Summary time plot (Castle et al. 1984) 
To identify patterns and incidence of ADRs, this method was 
recommended for the industrial context. It summarizes the plausible 
relationship between event and drug based on time factor. After 
analyzing enough information, a plot is made with the onset lag time 
of ADR and drug on X-axis and ADR severity on Y-axis. This method 
saves time and understandable with legible terminology and 
provides reliable results with minimal information. 
Limitation: This method majorly considers and summarizes the time 
factor and cannot provide conclusions based on other factors [29] 
Cibageigy method (Venulet et al.1980) 
After several consensus meetings, this method was proposed. 
Initially, this method was based on an analogous visual scale, later a 
checklist of 23 questions with three parts has been updated to this 
technique. (i) Current ADR History (ii) Previous ADR experience of a 
patient (iii) Consulting clinician experience. Compared to the initial 
Visual Analogue (VA) Scale (based on evaluator’s assessments), the 
updated method has a high acceptance rate. 
Limitation: Though the results are reliable, to assure validity of the 
knowledge and expertise of the evaluator reflect in the assessment [30]. 
Loupi et al. 1986 method 
This method is applicable in the assessment of the teratogenic 
potential of the drug. The Algorithm has been categorized into two 
sections on an axial basis. The first section allows excluding the drug 
if not plausible for the abnormality whereas the second section 
relies on the bibliographical data.  
Limitation: To conclude the results, alternative etiological reasons 
are being considered by three questions from the two sections 
irrespective of suspected drug and bibliographic data [31]. 
Maria and victorino (M and V) scale 
To diagnose drug-induced liver injury (DILI), Maria and Victorino 
developed this scale. Causal relationship was categorized as a score 
between 6 and 20 (score of>17, definite; 14-17, probable; 10-13, 
possible; 6–9, unlikely; <6, excluding hepatotoxic drugs). To acquire 
accurate results, it requires clinical expertise as the diagnosis of DILI 
is complex. Evaluation should be done separately for each drug in 
case of multiple suspected drugs. 
Limitation: It is difficult to generate scores for all types of DILI, as 
some questions are applicable only for immune allergic hepatitis in 
this scale [32]. 
Australian method 
Australian method concludes results from internal data available in 
the case reports on timing and laboratory findings. Deliberate 
exclusion of previous knowledge on the suspected drugs was done 
in the assessment.  
Limitation: Limitation of this method is the likelihood of causal 
relationships [33]. 
World Health Organization (WHO)–Uppsala Monitoring Centre 
(UMC) causality assessment criteria 
WHO causality assessment scale is majorly used scale for the 
assessment of the causal relationship of case reports and has been 
developed during the International Drug Monitoring Programme in 
discussion with national centers.  
This scale has been categorized into 6 groups considering the basic 
criteria of 4 requirements in each category. These 4 criteria include 
a) temporal relationship b) plausibility and absence of other factors 
c) laboratory findings and d) de-challenge and re-challenge. 
Unclassified is applicable when additional information is necessary 
to evaluate the relationship [11].  
Naranjo scale 
Naranjo scale assesses the causality using the traditional categories 
of definite, probable, possible and doubtful. A ten elemental 
questionnaire with yes, no and unknown replies are developed. 
Based on the replies, the score has been determined into categories.  
Limitation: The Naranjo Scale does not address the points needed in 
the assessment of the causality of possible drug interactions [34]. 
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Drug interaction probability scale (DIPS) 
Horn et al. proposed a DIPS scale to evaluate ADRs caused due to drug 
interactions. To estimate the likelihood of drug interactions, DIPS 
adopted ten questions with ‘yes’ or ‘no’ answers yielding a score. DIPS 
covers the information on pharmacological properties of the drug, 
patient profile and impact of other drugs through the questions. 
Limitation: Assessment of this scale can be done only by experts 
who have sound knowledge in pharmacological and 
pharmacokinetic profiles of involved drugs [35]. 
Bayesian adverse reactions diagnostic instrument (BARDI) 
To overpower the limitations of variability with skilled judgments 
and algorithms, the BARDI method was developed. This method 
evaluates posterior odds in favor of suspected drugs over other 
alternate factors. Posterior odd factor considers six subsets of 
assessment; the first subset (prior odds) deals with epidemiological 
data, clinical trial information and population pharmacokinetics, 
whereas the rest of the five subsets (likelihood ratios) deal with 
specific case report information.  
Either on paper or computer, this method can be demonstrated as a 
spreadsheet Programme. Instant feedbacks in numerical and graphical 
values are being calculated as soon as new evidence of suspected ADR 
is assessed. Case parameters of case findings and scoring are 
calculated in the spreadsheet by using the software. During the 
process, the spreadsheet allows rapid calculations.  
Limitation: Sometimes the results provide multiple causal associations 
with drug and event, even though operated by experts [36]. 
MacBARDI spreadsheet 
The computerized MacBARDI spreadsheet includes or needs five 
kinds of data: (i) Pure lines of data describing the required input; (ii) 
Input lines that are used as calculation criteria for each of the six 
variables; (iii) Assumption lines that are integrated inputs used in 
calculations; (iv) Lines of calculation for calculating and showing the 
significance of each term in the evaluation; (v) Output lines showing 
the value of each aspect needed to measure the posterior odds and 
the posterior evens itself. MacBARDI enables case analyses to be 
updated as and when fresh data is available. This method has all the 
necessary criteria for assessing causality (e. g. explicitness, 
flexibility), Promotes learning and modeling and significantly 
reduces the time needed to estimate cases. Other-Bayesian Adverse 
Reactions Diagnostic Instrument (BARDI) prototypes created for the 
diagnosis of ADRs comprise a risk forecast exemplary for pseudo-
allergic response and release of Histamine in patients experiencing 
surgery [31] as well as diagnostic assistance for pseudomembranous 
colitis [30]. The merits of BARDI are reliability (the same input 
information brings out the same output) explicitness and 
transparency (final results show undoubtedly what information is 
considered and its contribution in the evaluation) and an etiological 
balancing (all drug and non-drug possible causes are considered in 
the evaluation). 
Limitation: This approach's apparent limitations are the 
significant amount of time, resources and complex calculations 
involved [37]. 
Causality assessment of vaccine-related adverse events 
Vaccines require a high degree of safety and efficacy strategies 
as these are administered in healthy individuals, especially in 
neonates and infants for beneficiary outcomes. Though most of 
the adverse events due to vaccines are unavoidable, causality 
assessment has to be given utmost priority. Advisory Committee 
on Causality Assessment (ACCA) in Canada developed a method 
for vaccine-related events. ACCA receives the most unusual and 
serious adverse events due to vaccines. ACCA reviews every 
individual case in a methodological and systematic way to 
evaluate causal association on a form using specialists from 
various clinical and medical departments. This form consists of 
seven sections that focus on different parameters related to the 
importance of adverse reactions due to vaccine and its impact 
for further evaluation [38]. 
Karch and lasagna scale  
Karch and lasagna scale have been made known in the early 1970s 
and have a correlation to that of the WHO causality scale. Causality 
has been classified as definitive, probable, possible, conditional or 
unlikely. It has not been featured as there are no distinct advantages 
compared to other scales. Some of the studies had been conducted 
and the results of the studies found attributed to karch and lasagna 
scale over the WHO-UMC scale.  
Limitation: Duplicability and validity of results are not well 
established which will influence the quality of reports for further 
validation [39]. 
Begaud algorithm 
Begaud algorithm has been executed in France during the 1970s and 
evaluation depends on the three-stage process. It collaborates 
chronological and symptomatological evaluations to obtain a 3-
degree global score with principles of doubtful, possible and 
probable.  
Limitation: Begaud method deals with each drug as an individual 
case. Combinations of drugs cannot be taken into consideration. 
Reintroduction of the same drug or drug of the same class under 
various circumstances/conditions is not taken into as real re-
challenge [40].  
Hallas scale 
Although evaluating and identifying the ADRs is complicated, 
estimating the avoidability of ADRs in the course of therapy is 
further challenging. Hallas scale is a sequence of four statements 
concerning the estimation of avoidability of associated ADRs with 
drugs. This scale can be advantageous not only to determine how 
many degrees an ADR can be avoidable but also to evaluate 
treatment adherence towards standard guidelines.  
Limitation: For inpatients and therapy procedures where conditions 
are highly variable and chronic, the Hallas scale cannot be 
applicable. Thorough knowledge of treatment procedures with 
uninterrupted updating is needed to meet the criteria standards 
where it is dynamically changing. This makes the Hallas scale 
irreproducible and less reliable [41]. 
PRISCUS list 
PRISCUS List includes the list of potentially inappropriate 
medications (PIM) for geriatric patients. It consists of instructions 
for clinical practice and therapeutic alternatives. PRISCUS list was 
generated step by step of quality analysis, literature search, and 
development of preliminary PIM list. This preliminary list finally 
altered utilized Delphi method for validation. 
Limitation: Little scientific data is available for assessment of 
recommendations and alternate approaches. Validity and 
practicability are still to be developed of PRISCUS List as it is 
restricted to the German epidemiological scenario [42]. 
RUCAM scale 
The Roussel Uclaf Causality Assessment Method (RUCAM) is 
extensively used to evaluate the causal relationship between drugs 
and hepatic injury. It can be utilized for objective assessment of 
hepatotoxic drugs under development in the clinical trial settings. 
Limitation: Scoring system does not incorporate factors of age, 
alcohol dependence and other factors that diverge the results of the 
causal relationship of drugs with hepatic injury. It should be 
contrived in addressing the uncertainty of results eliminating other 
factors that cause liver injury [43]. 
CIOMS scale 
Council for International Organizations of Medical Sciences (CIOMS) 
scale has been contemplated as a standard causality assessment tool 
for Drug and herb induced liver injuries. The CIOMS scale has been 
recommended by eight scientists from 6 countries of hepatology 
specialization during a consensus meeting. Numerous advantages in 
using the CIOMS scale with its high specificity and validation 
regarding hepatotoxicity and its causative source with positive re-
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exposure test. This scale meets all the criteria for a valid causality 
assessment procedure for prospectively collected cases.  
Limitation: Risk factors for liver injury have been restricted to only 
alcoholism and age in CIOMS scale. Additional assistance to provide 
quality data in case of retrospective case collection. It has a very 
limited exclusion of other causes of hepatotoxicity [44].  
Liverpool ADR scale 
Gallagher et al. have developed the Liverpool ADR causality 
assessment tool depending on the criteria given by Sir Branford Hill. 
They demonstrated compatibility results with a few variable 
controversies with the Naranjo scale and high inter-rater reliability 
(IRR). This scale has a flow diagram arrangement rather than a 
scoring system, which makes to evaluate easier and quicker. 
Limitation: Validation of the tool has been done internally and not 
independently. This scale needs further validation and certainty of 
results by experts [45]. 
Visual Analogue Scale (Miremont et al. 1994) 
Visual analogue scale has been proposed by Miremont et al. and 
compared the thoughts of physicians with a standardized French 
causality assessment scale. A study has been conducted on 75 ADR 
cases involving 120 drugs. In the course of study, physicians 
presented results of ‘likely’ and ‘very likely’ for 60% of cases and 
‘unlikely’ or ‘possible’ for 32% of cases, whereas results of standard 
French causality model provided only 11% for ‘likely’ and 89% for 
‘possible’ or ‘unlikely’. Only 6% of cases are in complete accordance 
with both physicians and the standard methods. 
Limitation: Rate of agreement and lack of precision in decision 
making and was lower for intermediate causality levels [46].  
Blanc et al. 
Blanc et al. developed a decision table in 1979 to evaluate the nature 
of relationships amidst drugs and events. Time sequence, response 
pattern and role of the underlying disease(s) are three considerable 
factors for this table. By incorporating these three factors, it has 
been created with a five option causality scale ranging from doubtful 
to certain. The results presented by this scale have given very low 
concordance and are not outstanding [17]. 
Emanueli and sacchetti 
Emanueli and Sacheti have evolved an algorithm for the categorization 
of adverse events in clinical trials. This algorithm has been developed 
on the basic principle of the Karch and Lasagna scale. A 5 point scale 
decision table regulates the probability of the relationship between 
drug and event. Precision and reliability of results have confirmed to 
be higher and utilized in many large scale clinical trials. 
Limitations: It cannot rule out other causes like clinical state and 
other therapies, which makes it difficult to evaluate events that fall 
under the class of higher than possible [47].  
Stephens algorithm 
In 1984, Myles Stephens proposed the indicated algorithm to 
evaluate drugs that are under both pre-marketing and post-
marketing surveillance. It can also differentiate the suspected drugs 
from various concurrent drugs in assessing causality. It has been 
developed based on the criteria of kramer’s and Naranjo Scale [48]. 
CONCLUSION 
Many of the causality assessment methods have their own merits 
and demerits. The purpose of the development of standard ADR 
assessment methods is to implement reliable, reproducible and 
validated information regarding the association of adverse reactions 
and suspected drugs. Some of the scales may serve their purpose to 
a major extent; however, no single scale has been adopted as 
standardized and considered for uniform acceptance. However, 
WHO causality assessment scale and Naranjo probability scale are 
the widely used and commonly preferred in most of the practices. 
ABBREVIATIONS 
ADR–Adverse Drug Reaction, VA–Visual Analogue, DILI-Drug 
Induced Liver Injury, WHO-World Health Organization, UMC-
Uppsala Monitoring Center, DIPS-Drug Interaction Probability Scale, 
BARDI-Bayesian Adverse Reactions Diagnostic Instrument, ACCA-
Advisory Committee on Causality Assessment in Canada, PIM–
Potentially Inappropriate Medications, RUCAM-Roussel Uclaf 
Causality Assessment Method, CIOMS-Council for International 
Organizations of Medical Sciences, IRR-High Inter-Rater Reliability 
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